Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 2:29 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 4,268 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: ADM Clear all

Conditions: Traumatic Brain Injury
Interventions: Sildenafil Citrate 50Mg Tab, functional Near-infrared Spectroscopy (fNIRS), Carbon Dioxide (CO2) 5%, Neuropsychological Assessments, Gadolinium contrast infusion, Blood sample collection for research purposes, Structural brain Magnetic Resonance Imaging (MRI; Drug · Device · Other + 1 more
Lead sponsor: Uniformed Services University of the Health Sciences; Federal
Eligibility: 18 Years to 55 Years
Enrollment: 1 participant
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Early Literacy, Articulatory Gestures, Phonemic Awareness
Interventions: phonemic segmentation; Behavioral
Lead sponsor: Montclair State University; Other
Eligibility: 48 Months to 59 Months
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Montclair, New Jersey

Conditions: Prostate Cancer
Interventions: NanoKnife Procedure; Device
Lead sponsor: Angiodynamics, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 2
States / cities: Chicago, Illinois • Rochester, Minnesota

Conditions: Appendectomy, Appendicitis, Appendicitis Acute
Interventions: Infection-Prediction Algorithm; Device
Lead sponsor: Ann & Robert H Lurie Children's Hospital of Chicago; Other
Eligibility: 3 Years to 18 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 4
States / cities: Chicago, Illinois • Maywood, Illinois • Winfield, Illinois

Conditions: Diffuse Large Cell Lymphoma, Burkitt's Lymphoma, High Grade B-cell Lymphoma
Interventions: Rituximab, IT Cytarabine; Drug
Lead sponsor: New York Medical College; Other
Eligibility: 3 Years to 31 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 5
States / cities: Buffalo, New York • Valhalla, New York • Charlotte, North Carolina + 2 more

Conditions: Suicide
Interventions: Continuous Identity Cognitive Therapy (CI-CT), General Health Education; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Genetics
Interventions: Not listed
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: 18 Years to 115 Years
Enrollment: 1,258 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Atrial Fibrillation (AF), Atrial Flutter
Interventions: Cardiac computed tomography angiography, Standard of care management; Diagnostic Test · Other
Lead sponsor: Ottawa Heart Institute Research Corporation; Other
Eligibility: 18 Years and older
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Stage 1 cT1b-T1cN0M0, Triple Negative Breast Cancer
Interventions: Carboplatin, Paclitaxel, Pembrolizumab, Doxorubicin, Cyclophosphamide; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cognition, Concentration, Attention, Focus
Interventions: Cognitive Nutritional Supplement, Placebo; Dietary Supplement · Other
Lead sponsor: Pharmavite LLC; Industry
Eligibility: 25 Years to 65 Years
Enrollment: 422 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Addison, Illinois

Conditions: Endometrial Carcinoma, Ovarian Carcinoma, Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma, Cervical Carcinoma
Interventions: AL3818, Paclitaxel, Pegylated Liposomal Doxorubicin (PLD), Topotecan, Carboplatin; Drug
Lead sponsor: Advenchen Laboratories, LLC; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 294 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 8
States / cities: Long Beach, California • Miami, Florida • Lexington, Kentucky + 5 more

Conditions: Lymphoblastic Lymphoma
Interventions: Prednisone, Vincristine, Daunorubicin, PEG-asparaginase, Erwinia asparaginase, Doxorubicin, Cyclophosphamide, Cytarabine, Thioguanine, Clofarabine, Methotrexate, Mercaptopurine, Dexamethasone, Hydrocortisone, Etoposide; Drug
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 21 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2022
U.S. locations: 2
States / cities: San Diego, California • Memphis, Tennessee

Conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions: filgrastim, graft-versus-tumor induction therapy, rituximab, therapeutic allogeneic lymphocytes, cyclophosphamide, cyclosporine, cytarabine, doxorubicin hydrochloride, etoposide, fludarabine phosphate, prednisone, vincristine sulfate, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Breast Cancer
Interventions: Taxotere/Docetaxel, Adriamycin/Cytoxan, doxorubicin; Drug
Lead sponsor: Mothaffar Rimawi; Other
Eligibility: 18 Years and older · Female only
Enrollment: 167 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Infant Development, Cerebral Palsy, Motor Disorders, Neurological Disorder
Interventions: Observational; Other
Lead sponsor: Ann & Robert H Lurie Children's Hospital of Chicago; Other
Eligibility: 10 Weeks to 20 Weeks
Enrollment: 350 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: ALL, Childhood, Lymphoblastic Lymphoma, Childhood, Lymphoblastic Leukemia, Acute, Childhood
Interventions: Ixazomib, Vincristine, Dexamethasone, Asparaginase, Doxorubicin, Methotrexate (IT), Triple IT (Methotrexate, Hydrocortisone, Cytarabine), Leucovorin; Drug
Lead sponsor: Therapeutic Advances in Childhood Leukemia Consortium; Other
Eligibility: 1 Year to 21 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 17
States / cities: Los Angeles, California • Orange, California • Washington D.C., District of Columbia + 14 more

Conditions: Cancer of Lung, Cancer of the Lung, Lung Cancer, Neoplasms, Lung, Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Cancer, Non-Small-Cell Lung Carcinoma
Interventions: Microwave Ablation; Device
Lead sponsor: Ethicon, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 5
States / cities: Duarte, California • Rochester, Minnesota • New York, New York + 2 more

Conditions: Depression, Depressive Symptoms, Cardiovascular Disease (CVD), Coronary Artery Disease (CAD), Heart Disease
Interventions: Beating the Blues (BtB), Usual Care; Behavioral · Other
Lead sponsor: Indiana University; Other
Eligibility: 40 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Surveys, Usability, Healthy
Interventions: e-PRO App; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hepatitis C
Interventions: Patient-Centered Electronic App; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 308 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Acute Myocardial Infarction
Interventions: Not listed
Lead sponsor: Scripps Translational Science Institute; Other
Eligibility: 18 Years to 80 Years
Enrollment: 664 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2025
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Multiple Myeloma
Interventions: VELCADE, Doxil, Dexamethasone; Drug
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Safety Issues, Injuries, Car Accident
Interventions: CIAS (Computer Intervention Authoring Software), Standard Printed Discharge Instructions; Behavioral
Lead sponsor: Lifespan; Other
Eligibility: Up to 21 Years
Enrollment: 295 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Diabetes Mellitus, Type 2
Interventions: Diabetes self-management program for Hispanics and their families, General health educational program for Hispanics and their families; Behavioral
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years to 99 Years
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Columbus, Ohio

Search by objective public record fields.

Cerebrovascular Reactivity Assessed With fNIRS as a Biomarker of TCVI After Acute Traumatic Brain Injury in Military

The Effect of Articulatory Gestures on Early Literacy Skills in 4-year Olds

Study of NanoKnife for Ablation of Prostate Cancer in Intermediate Risk Patients

Early Detection of Infection Using the Fitbit in Pediatric Surgical Patients

Treatment for Advanced B-Cell Lymphoma

Development of a Recovery Oriented Treatment for Post-Acute Suicidal Episode (PASE) Veterans

Physicians' Understanding of Human Genetic Variation

Left Atrial Imaging Prior to Cardioversion: Leveraging Computed Tomography to Rule Out Thrombus in The Emergency Department (LA CLOTTED)

Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer

A Clinical Trial to Assess Cognitive Effects of Cognitive Nutritional Supplement in General Population

Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)

NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma

T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies

Taxotere and Adriamycin/Cytoxan (AC) Validation in Breast Cancer Patients

Families Filming Infants Learning Movement

PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

NEUWAVE Flex Microwave Ablation System in the Ablation of Primary Soft Tissue Lesions of the Lung

Beating the Blues for Your Heart

Usability and Satisfaction With an Electronic Survey Administration Application in General Population

Use of a Patient-Centered Electronic App to Increase ED Patient's Knowledge on HCV to Improve the HCV Care Continuum

Molecular and Morphologic Characterization of Circulating Endothelial Cells

Study of Combination Therapy With VELCADE, Doxil, and Dexamethasone (VDd) in Multiple Myeloma

Buckle Me Up!: A Digital Emergency Department Discharge Intervention for Child Car Safety

A Family-Based Diabetes Intervention for Hispanic Adults in an Emerging Community